Clinical Validation of Suntech Advantage MX With Suntech Neonate and Children Cuff Line
Clinical Validation of Suntech Advantage MX With Suntech Neonate and Children Cuff Line Against Invasive Intra-arterial Reference According to the ANSI/AAMI/ISO 810602-2019 Protocol for Neonates, Infants, Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Contacts and Locations
Study Contact
Study Contact
- Name: Lindsay Carlson
- Phone Number: 19196542330
- Email: lcarlson@suntechmed.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital of Los Angeles
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- At least 3 subjects shall be < 1,000g in weight.
- At least 3 subjects shall be 1,000g to 2,000g in weight.
- At least 3 subjects shall be >2,000g
- At least 3 subjects shall be ≥ 29 days and < 1 year of age.
- At least 3 subjects shall be ≥ 1 year and < 3 years of age.
Exclusion Criteria:
- Subjects who study personnel determine invasive blood pressure measurements will be unreliable
- Patients found to have a-fib, irregular heart rhythm, dysrhythmias, bigeminy, trigeminy, and isolated premature ventricular beats (VPBs) during the enrollment process are to be ineligibile to participate in the study
- Patients who are prescribed anti-coagulation medication during the enrollment process or begin anti-coagulation medication after enrollment are ineligible to participate in the study.
- Exclusions can also occur post-data review based on exclusion criteria according to ANSI/AAMI/ISO 81060-2:2019
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
At least 3 subjects shall be <1,000g in weight
|
no intervention will be provided.
|
|
At least 3 subjects shall be 1,000g to 2,000g in weight
|
no intervention will be provided.
|
|
At least 3 subjects shall be >2,000g
|
no intervention will be provided.
|
|
At least 3 subjects shall be >/= 29 days and < 1 year of age
|
no intervention will be provided.
|
|
At least 3 subjects shall be >/= 1 year and <3 years of age
|
no intervention will be provided.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The blood pressure measurement
Time Frame: approximately 1 hour
|
collected from the Advantage MX module matches the intra-arterial line data
|
approximately 1 hour
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Advantage MX Neonate-Infant
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
NCT04863508RecruitingHypertension,Essential | Hypertension, Masked
-
NCT07598760Not yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEF
-
NCT07566650Not yet recruiting
-
NCT07486453Not yet recruitingPrimary Hypertension
-
NCT07147595CompletedHypertension (HTN) | Hypertension Arterial
-
NCT05395403CompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White Coat
-
NCT07487441Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)
-
NCT07577973Not yet recruiting
-
NCT07399912Enrolling by invitationHypertension,Essential
-
NCT07363447CompletedHypertension | Arterial Hypertension | Systemic Hypertension
Clinical Trials on Advantage MX Module
-
NCT06117865Active, not recruitingIBS - Irritable Bowel Syndrome
-
NCT07534930Active, not recruitingIBS (Irritable Bowel Syndrome) | DGBI
-
NCT06059092Not yet recruitingWellbeing | Emotional Distress | Psychosocial Problem | Functional Impairment | User Experience
-
NCT02210546Unknown
-
NCT00763919Completed
-
NCT06850857Enrolling by invitationMandible Fracture | Facial Injuries | Orbital Fractures | Le Fort | Orbital Floor Fracture | Facial Laceration | Nasal Fracture | Zygomaticomaxillary Complex Fracture | Zygoma Fracture
-
NCT00830310Completed
-
NCT04474509Recruiting
-
NCT07047222CompletedMenstrual Irregularity | Dysmenorrhea | Premenstrual Syndrome-PMS
-
NCT04736264RecruitingPrimary Open Angle Glaucoma | Primary Angle Closure Glaucoma